Group B streptococci (GBS) are the leading causes of neonatal sepsis and meningitis in the United States, with a high rate of fatality and serious morbidity despite appropriate therapy. The C-protein antigens of GBS appear to be important in immunity to experimental infection, yet these antigens remain incompletely characterized with respect to their number, structure, and function. None of these proteins has yet been purified to homogeneity. We have developed a novel method for extraction of surface proteins from the A909 (Ia/c) strain of GBS by using mutanolysin. Antibodies raised in rabbits against these partially purified proteins conferred passive protection to lethal GBS infection in mice challenged with a GBS strain expressing C proteins with a heterologous capsule type. In addition, mouse monoclonal antibodies were produced and identified by reactivity with the mutanolysin-extracted proteins. One of these monoclonal antibodies (4G8) identifies an epitope on the alpha-antigen of the GBS C proteins (identified by protease susceptibility and mouse protection). On sodium dodecyl sulfate-polyacrylamide gels, this epitope appears as a series of regularly spaced bands ranging in apparent molecular mass from 160,000 to 30,000 Da. The monoclonal antibody 4G8 induces opsonic killing of GBS and protects mice from lethal challenge with GBS. Thus, the 4G8 monoclonal antibody identifies a fully protective epitope on the C-protein alpha-antigen of GBS.
Group B streptococci (GBS) are the leading causes of neonatal sepsis and meningitis in the United States and have a worldwide distribution (1, 31) . The C proteins of GBS, first recognized by Wilkinson (32) , are present in approximately 60% of clinical isolates of GBS (17) and are immunogenic and protective against infection in animal models (21) . These antigens, originally designated Ibc protein because of their presence on lb and Ic (now Ia/c) strains of GBS, have never been fully characterized. Their size, number, structure, function, and virulence properties remain largely unknown. Other proteins present on certain strains of GBS include the R and X proteins, which have not been definitively shown to be protective antigenic determinants (22) .
Several investigators have attempted to characterize the C-protein antigens of GBS. Techniques used to examine these antigens have included extraction into hot hydrochloric acid, detergent solubilization, and examination of proteins from the broth of growing GBS (3-5, 21, 28, 32) . Proteins that are immunoreactive with polyclonal C-protein antisera have been reported in a range of 12 to 180 kDa. At least two C-protein antigens (designated alpha and beta) have been recognized by differential trypsin susceptibility and were shown to be expressed independently on different strains (5). Russell-Jones and colleagues (28, 29) reported that the beta-(trypsin-susceptible) antigen is a detergentextractable protein with a molecular mass of 130 kDa and binds to the Fc region of human immunoglobulin A (IgA). Recently, two additional C-protein antigens (gamma and delta) have been proposed on the basis of serologic data (8) . It has been suggested that C proteins may enhance virulence of GBS (26, 27) .
Cleat and Timmis (13) reported the expression in Escherichia coli of recombinant GBS proteins that were immuno-* Corresponding author.
reactive with polyclonal antisera to alpha and beta C-protein antigens but did not demonstrate that these proteins were capable of eliciting protective immunity. Valtonen and colleagues (30) reported isolating a 14-kDa protein from the broth of a Ia/c strain of GBS that was capable of evoking mouse-protective antibodies. These researchers noted that antiserum raised against this polypeptide reacted with larger proteins extracted from GBS and speculated that the 14-kDa protein was a fragment of a larger protein.
Mutanolysin, a muralysin derived from Streptomyces globisporus, has been shown to cleave the cell wall of GBS and has been previously used for the purification of the polysaccharide capsule of this bacterium (11, 33) . It appeared reasonable that mutanolysin could also be used to isolate surface-associated proteins from GBS under less harsh conditions and with greater preservation of native epitopes than with detergents or hot acid extraction. As the enzymatic extraction liberated a large number of proteins from GBS, only a subset of which were likely to be C proteins, we thought that monoclonal antibodies could assist in the recognition of individual proteins and might identify protective epitopes. In addition, monoclonal antibodies might reveal epitopes that are shared by or unique to individual C proteins. While monoclonal antibodies recognizing C proteins have previously been described (14, 28) , any protective activity of these antibodies has not been reported.
We report a novel method for the extraction of proteins from the A909 (Ta/c) strain of GBS, using mutanolysin. We demonstrate that partially purified enzyme-extracted proteins are capable of eliciting antibodies protective against GBS infection in an animal model. A monoclonal antibody that recognizes a subset of these proteins induces in vitro opsonic killing of a C-protein-containing strain of GBS and confers protection in mice against lethal challenge with GBS, thus identifying a fully protective epitope of the GBS C-protein alpha-antigen. Isolation of surface proteins from A909. The A909 strain of GBS was grown into stationary phase in 14 liters of dialysate of Columbia broth in a fermentor with the pH titrated to remain at 7.2. Bacterial cells were harvested, washed in phosphate-buffered saline (PBS), and resuspended in 1/20 the volume of 0.3 M potassium phosphate buffer-40% sucrose (pH 7.0); 560 U of mutanolysin (Sigma) was added and allowed to incubate overnight at 37°C with gentle stirring. Protoplasts were formed and removed by centrifugation. The supernatant was allowed to dialyze against deionized water, and a yellow-white precipitate formed. The precipitate was pelleted at 10,000 x g for 20 min and lyophilized. In order to characterize the antigens, further treatment of the extract with proteases was performed by the method of Wilkinson (32) as follows: digestion with trypsin (Sigma) (substrate/enzyme ratio = 4:1) in 50 mM Tris buffer (pH 8.0) for 2 h at 37°C. Digestion with hog gastric pepsin (Sigma) (substrate/enzyme ratio = 4:1) occurred in 50 mM citrate phosphate buffer (pH 2.5) for 2 h at 37°C.
Fractionation by column chromatography. The lyophilized powder was dissolved in 8 M urea. A solution of 5 mg/ml in 8 M urea-0.05 M Tris buffer (pH 7.4) was fractionated with a Sephacryl S-300 column (1.8 by 90 cm; Pharmacia) (16) . Protein elution was monitored by A280, and three peaks were noted. These were pooled, dialyzed against deionized water, and lyophilized.
Immunization of rabbits. New Zealand White rabbits were immunized with whole bacteria treated with Formalin as described by Lancefield et al. (21) or with the column fractions of the A909 surface extract emulsified in complete or incomplete Freund adjuvant or in normal saline according to the following schedule: day 1, 100 p,g in complete Freund adjuvant subcutaneously; day 3, 100 ,ug intravenously; day 5, 100 p.g intravenously; day 7, 100 ,ug in incomplete Freund adjuvant subcutaneously; day 14, 100 p.g intramuscularly.
Serum was obtained from the anesthetized rabbits at day 21 by cardiac puncture.
Mouse protection tests. The mouse protection method was adapted from Lancefield et al. (21) . In brief, groups of 5 or 10 CD-1 outbred female mice (Charles River Laboratories, Wilmington, Mass.) of 6 to 8 weeks of age (approximately 25 g) were administered 1 ml of dilute antiserum or monoclonal antibody by intraperitoneal injection. Mice were challenged 24 h later with either 5 x 104 H36b (Ib/c) GBS or 5 x 108 515 (Ia) GBS. These inocula were determined to be the 90% lethal dose (LD90) for these strains in unimmunized mice.
Survivors were counted daily for 5 days.
SDS-PAGE and Western blotting (immunoblotting). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed by the method of Laemmli (19) . Gels had a 10 to 20% linear gradient of polyacrylamide, and electrophoresis was performed with a Hoeffer Mighty Small apparatus. Protein bands were visualized with Coomassie brilliant blue dye. Alternatively, electroblotting to nitrocellulose was performed by using 25 mM sodium phosphate (pH 6.5) and carried out either overnight at 125 mA or for 3 h at 300 mA. After being blocked with 5% skim milk in PBS containing 0.5% Tween 20, the blots were allowed to react with antiserum at dilutions of 1:100 to 1:500 in the same buffer. After reaction with goat anti-rabbit or anti-mouse IgG-alkaline phosphatase conjugate diluted 1:500, bands were visualized by the method of Blake et al. (7) (Fig. 1) . The range of molecular masses represented by these surface proteins is comparable with the ranges reported in previous studies that used either detergents or acid extraction (28) . 1 mg/ml in deionized water, PBS, or 3% Triton X-100; however, it was soluble in either 8 M urea or 6 M guanidine. Gel filtration column chromatography was performed on a 1-mglml solution in 8 M urea buffered with 0.05 M Tris (pH 7.4) with the use of a Sephacryl S-300 (Pharmacia) column (1.8 by 90 cm) equilibrated with the same buffer. There were three peaks detected in A280 (Al, A,,, and A,,,) (Fig. 2) . The peak fractions were pooled and dialyzed extensively against distilled H20, and the resultant slurries were lyophilized. The insoluble pools were suspended in a sample buffer containing Tris and SDS and were subjected to SDS-PAGE (Fig. 2) were raised against fractions A,, and A,,,. The capacity of these antisera to protect from infection with a GBS strain of different capsular type but homologous for C protein was tested in a mouse protection assay, the method initially used by Lancefield et al. to define C proteins (21) . The results of this assay are shown in Table 1 and demonstrate that the A,, antiserum was protective at a dilution of 1:20 and the A,,,
antiserum was protective at a dilution of 1:5. Although the A,,, fraction was enriched for a single 14-kDa protein, antiserum raised to this fraction recognized a large number of bands of higher molecular mass in the mutanolysin extract (Fig. 3, lane 1) . Antiserum to A,, also recognized a large number of bands (Fig. 3, lane 2) . Preparation of monoclonal antibodies. In order to study individual protein epitopes and to establish the possibility of shared epitopes in the proteins observed in the surface protein extract, monoclonal antibodies were developed. Monoclonal antibodies were prepared by using intact GBS strain A909 that had been treated with Formalin. Hybridoma clones were screened by ELISA, with the mutanolysin extract as antigen. One of these monoclonal antibodies, 4G8, was identified as an IgG2a kappa antibody and was chosen for further study because of the pattern observed in Western blots against the surface protein extract of the A909 strain of GBS (Fig. 3, lane 3) . The antibody identified a series of regularly spaced bands ranging in apparent molecular mass from 30 to approximately 160 kDa at approximately 8-kDa intervals. Absorption of high-titered ascitic fluid containing 4G8 by the intact Ia/c strain A909 but not by the Ta strain 090 extensively removed reactive antibodies, as determined by ELISA. (Titer was reduced from 1:106 to <1:102). Removal of the antibody by intact bacteria supports the surface localization of the epitope.
In vitro and in vivo protective activity of the 4G8 monoclonal antibody. After purification of IgG from ascitic fluid with a protein A-Sepharose column, 4G8 antibody was tested for functional activity in an opsonophagocytic assay. Table 2 shows that the 4G8 antibody at concentrations of 2 to 200 jig/ml significantly reduced the number of CFUs of strain A909 GBS compared with an irrelevant monoclonal antibody (9BG5 directed against a viral antigen [10] ) of the same class, subclass, and light-chain type and at the same concentrations. Killing was reduced at lower antibody concentration (0.2 j.ig/ml). Inactivation of the complement by heating to 56°C for 30 min eliminated killing by the 4G8 monoclonal antibody, thereby demonstrating that the killing is complement dependent (data not shown). The 4G8 monoclonal antibody was then tested for its ability to protect mice against lethal infection with GBS. In pilot experiments, a dose-survival curve was established for the 4G8 antibody in the mouse protection assay, using the H36b strain (Tb/c) as the challenge strain. Enhanced survival was observed at doses as small as 10 ,ug per mouse when compared with mice receiving saline. To make certain that this effect was not due to the presence of nonspecific antibody, the effect of 100 jig of 4G8 antibody was compared with that of 100 ,ug of the irrelevant mouse monoclonal antibody (9BG5). A dose of 100 ,jg of 4G8 monoclonal antibody delivered intraperitoneally significantly enhanced the ability of mice to survive challenge with a C-proteincontaining strain of GBS when compared with 9BG5 (Table  3) .
Presence of the protective epitope on the alpha-antigen. Previous work on C proteins has distinguished between a trypsin-sensitive beta-antigen and a trypsin-resistant alphaantigen (31) . In order to determine whether the epitope recognized by the 4G8 was on the alpha-or beta-antigen, the mutanolysin extract of GBS strain A909 was treated with pepsin or trypsin. Western blots were performed with these preparations and probed with the 4G8 monoclonal antibody (Fig. 4) . The bands that react with the 4G8 antibody are susceptible to pepsin but not trypsin digestion. Bands of lower molecular mass also appeared on the Western blot after treatment with trypsin. This indicates that a portion of the protein is cleaved by trypsin but that antigenicity is retained after treatment. There were no immunoreactive bands seen after pepsin treatment, indicating that this treatment destroyed the epitope. These proteins are therefore consistent with the definition of the alpha-antigen of GBS C protein, which is distinguished from the beta-antigen by virtue of its resistance to trypsin degradation. In addition, monospecific antibody directed against the alpha-antigen (6) (kindly provided by Lars Bevanger, Trondheim, Norway) was used to immunoblot the mutanolysin extract and showed a stepladdering pattern of bands identical to that of the 4G8 antibody, further establishing this epitope on the alpha-antigen (Fig. 3, lane 4) . In order to show that the antigen recognized by the 4G8 monoclonal antibody was specific for the C-protein alphaantigen, we sought to demonstrate that the antibody does not 1 
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- bind to the C-protein beta-antigen. We used a modification of the method of Russell-Jones et al. (29) to extract the betaantigen into detergent (SDS in this case). An extract from the A909 strain contained a band with a molecular mass of 130 kDa, easily visible on Coomassie brilliant blue-stained gel, which was absent in the control Ia strain 090. The identity of the antigen was confirmed by immunoblotting with human myeloma IgA (Fig. 5) . There was no reaction between this preparation and the 4G8 monoclonal antibody in immunoblots (Fig. 5) , indicating that this monoclonal antibody does not recognize beta-antigen in this preparation.
DISCUSSION
Virulence of and immunity to the group B streptococci has traditionally been addressed in terms of the well-described capsular polysaccharide (18) . In other streptococci, especially group A streptococci, surface proteins appear to play a dominant role in immunity. The M protein is now known to be a virulence factor for group A streptococcal infection and has antiphagocytic activity (20) . Type-specific immunity to the M protein is protective against infection. Pneumococcal surface protein A has also been explored as an antigenic determinant and virulence factor in Streptococcus pneumoniae, and antibody to this protein appears to confer protection from pneumococcal infection independently of anticapsular antibody (9, 23) . Because of the difficulty in eliciting protective levels of antibody in some recipients after immunization with purified GBS polysaccharides, the protein antigens that are capable of eliciting protective immunity take on additional importance as potential vaccine components. It has also been suggested that C proteins are virulence factors for GBS infection: type II strains that are C protein positive appear to evade in vitro opsonization (26) and phagocytosis (27) better than strains that lack C protein. C-protein-positive strains have also been shown to predominate in early neonatal infection (12) .
In this study, proteins were enzymatically extracted from the A909 strain of GBS and shown to contain protective antigens; these proteins could be used to immunize rabbits, and these antisera were protective against experimental infection with a strain of heterologous capsule type. Thus this extract contains, by definition, C proteins (i.e., seroreactive with C-protein antiserum and capable of eliciting protective immunity). These findings represent the first time that C proteins have been enzymatically extracted from the surface of GBS and shown to confer protective immunity. A monoclonal antibody which recognizes a trypsin-resistant, pepsin-susceptible group of these proteins induces killing in an opsonophagocytic assay and protects against lethal infection in a mouse model. These results indicate that the proteins recognized by the monoclonal antibody are C proteins. Earlier work by Bevanger and Naess (6) demonstrated that an alpha-antigen-specific antiserum delayed, but did not prevent, death in mice challenged with GBS. They found partial protection with this antiserum; however by day 5, 78% of the challenged mice died. Monoclonal antibody 4G8 protected 90% of the mice at 5 days. These differences may be due to differences in antibody titer, assay conditions, or epitope specificity between the polyclonal serum and the monoclonal antibody. It is interesting to note that in the opsonophagocytic assay, increases in the concentration of 4G8 above 2 ,xg/ml did not appear to increase the killing of the GBS. This may represent saturation of the antibodybinding sites on the bacteria.
Since multiple bands are recognized by the 4G8 monoclonal antibody, each band must contain an identical epitope. This is consistent with the possibility that the multiple bands seen on Western blots represent fragments of a larger protein. The M protein of group A streptococci has been shown to contain a region that is variably repeated within the same organism (15) . The IgA protease of Streptococcus sanguis has recently been shown to contain a 20-amino-acid sequence which is repeated 10 times in the protein (14a). The appearance of regularly spaced bands on Western blots with monoclonal antibody 4G8 leads us to speculate that the GBS C-protein alpha-antigen contains a repeating domain that is either variably expressed or variably degraded, perhaps by proteolysis, thus accounting for the variation seen in molecular mass. An alternative explanation would be that the protein is covalently attached to some other regularly repeating structure, such as capsule or peptidoglycan. We find this latter possibility less likely, since such glycoproteins have not been described in similar bacteria.
The bands recognized by the 4G8 monoclonal antibody are resistant to trypsin digestion but susceptible to pepsin. This finding establishes that they are indeed proteins and that they represent the alpha-antigen or trypsin-resistant antigen described initially by Wilkinson (32) . Previous attempts to isolate this antigen have yielded confusing results. RussellJones and Gotschlich described a heterogeneous collection of proteins extracted by detergent from the A909 strain of GBS (ranging in molecular mass from 20 to 120 kDa) that immunoreacted with both polyclonal antiserum and a monoclonal antibody. The protective nature of these antigens was not explored. The researchers speculated that the multiple bands represented the breakdown product of a larger parent. Cleat and Timmis (13) reported the expression in E. coli of a protein from cloned GBS genomic DNA that immunoreacted with polyclonal antiserum to the alpha component. This protein was described as a diffuse band of approximately 190 kDa by SDS-PAGE. Again, the protective nature of this protein was not explored. In contrast, the trypsin-susceptible or beta-antigen appears to exist as a discrete 130-kDa protein that binds to human IgA and does not react with the 4G8 antibody.
Monoclonal antibody 4G8 directed to a protective C-protein epitope should serve as a valuable tool for further research. The function of the C-protein alpha-antigen remains unknown. This monoclonal antibody will allow the substructure of the alpha-antigen to be explored and this antigenically important domain to be distinguished from other domains, such as structural regions or areas that are not surface exposed. The antibody may prove useful in attempts to detect variant proteins that immunoreact with polyclonal sera but fail to be recognized by the monoclonal antibody. The antibody may also allow the cloning and expression of the protective region of the GBS C-protein alpha-antigen.
